ALPN - Alpine Immune Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.18
+0.67 (+7.05%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close9.51
Open9.53
Bid10.25 x 800
Ask10.32 x 1100
Day's Range9.20 - 10.24
52 Week Range2.05 - 15.00
Volume186,573
Avg. Volume800,726
Market Cap189.225M
Beta (5Y Monthly)1.68
PE Ratio (TTM)N/A
EPS (TTM)-1.88
Earnings DateMay 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Alpine Begins Dosing in Phase I Study for Advanced Malignancies
    Zacks

    Alpine Begins Dosing in Phase I Study for Advanced Malignancies

    Alpine (ALPN) doses the first patient in the phase I NEON-1 study evaluating its pipeline candidate ALPN-202 for treating patients with advanced malignancies.

  • Business Wire

    Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies

    Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies

  • Alpine Skyrockets on License Deal With AbbVie for ALPN-101
    Zacks

    Alpine Skyrockets on License Deal With AbbVie for ALPN-101

    Alpine (ALPN) signs an agreement with AbbVie granting exclusive worldwide option and license to its pipeline candidate, ALPN-101. The deal significantly boosts Alpine's funds.

  • Company News for Jun 19, 2020
    Zacks

    Company News for Jun 19, 2020

    Companies in the news are: SPOT, ALPN, AESE, NEON

  • The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs
    Benzinga

    The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 18) * ADC Therapeutics SA (NYSE: ADCT) * Adverum Biotechnologies Inc (NASDAQ: ADVM) * Alpine Immune Sciences Inc (NASDAQ: ALPN)( announced a licensing agreement with AbbVie Inc (NYSE: ABBV) * Amicus Therapeutics, Inc. (NASDAQ: FOLD) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * BioXcel Therapeutics Inc (NASDAQ: BTAI) * Burning Rock Biotech Ltd (NASDAQ: BNR) * Castle Biosciences Inc (NASDAQ: CSTL) * Cytokinetics, Inc. (NASDAQ: CYTK) * DiaMedica Therapeutics Inc (NASDAQ: DMAC) * Fennec Pharmaceuticals Inc (NASDAQ: FENC) * Neoleukin Therapeutics Inc (NASDAQ: NLTX) * Neubase Therapeutics Inc (NASDAQ: NBSE) * Ocular Therapeutix Inc (NASDAQ: OCUL) * Ovid Therapeutics Inc (NASDAQ: OVID) * Passage Bio Inc (NASDAQ: PASG) * Pliant Therapeutics Inc (NASDAQ: PLRX) * Protagonist Therapeutics Inc (NASDAQ: PTGX) * Royalty Pharma plc (NASDAQ: RPRX) (IPOed Monday) * Sarepta Therapeutics Inc (NASDAQ: SRPT)(announced a licensing agreement with Selecta Biosciences Inc (NASDAQ: SELB) for licensing the latter's immune tolerance platform, ImmTOR for use in Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies) * Tandem Diabetes Care Inc (NASDAQ: TNDM) * TELA Bio Inc (NASDAQ: TELA) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) * Trevena Inc (NASDAQ: TRVN) * Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 18) * CALLIDITAS THER/S ADR (NASDAQ: CALT)Stocks In Focus Mylan Wins Patent Lawsuit Against Biogen With Respect To Multiple Sclerosis Drug Mylan NV (NASDAQ: MYL) said the U.S. District Court for the Northern District of West Virginia ruled in its favor by invalidating Biogen Inc's (NASDAQ: BIIB) Tecfidera patent, U.S. Patent No. 8,399,514, for lack of written description. Mylan noted that the patent pertains to methods of treating multiple sclerosis using a dose of 480 mg/day of dimethyl fumarate delayed release capsules, and would have disallowed generic competition until 2028.With the patent win, Mylan is allowed to launch of its dimethyl fumarate product upon the receipt of FDA approval.In pre-market trading Friday, Mylan shares were rising 2.27% to $16.70.Assembly Biosciences Regains Rights To Gastrointestinal Programs After AbbVie Terminates Deal Assembly Biosciences Inc (NASDAQ: ASMB) said it will regain worldwide rights to all microbiome gastrointestinal programs, including ABI-M201 and ABI-M301, licensed under its collaboration agreement with AbbVie's Allergan. The development follows AbbVie deciding to terminate the R&D, collaboration and license agreement. This decision was not based on any efficacy, safety, or other data related to the collaboration programs, Assembly Biosciences said.ABI-M201 is currently being evaluated in a Phase 1b trial in patients with mild to moderate ulcerative colitis and ABI-M301 is a preclinical program for Crohn's disease, the company said. The transition is expected to be completed in the fourth quarter of 2020.In pre-market trading, Assembly Biosciences shares were rising 1.95% to $22.50.Tiziana to Get Patent For Platform Technology For Oral Administration Of Fully Human Monoclonal Antibodies Tiziana Life Sciences plc (NASDAQ: TLSA) announced the United States Patent and Trademark Office has granted a patent covering its proprietary platform technology for the oral administration of Foralumab, its proprietary fully human monoclonal antibody, and all other anti-CD3 monoclonal antibodies. The CD3 (cluster of differentiation 3) is a protein complex on T-cells, which is important for regulation of immune system, the company added. The patent will be issued by the USPTO June 23.The stock rallied 16.09% to $7 in pre-market trading.Roche Reports Positive Results For Late-Stage Prostate Cancer Study Roche Holdings AG Basel ADR (OTC: RHHBY) said the phase 3 IPATential150 study that evaluated ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care plus placebo met its co-primary endpoint of radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer and whose tumours had PTEN loss.The company said overall survival benefit and additional secondary endpoints are not yet mature and the trial will continue until the next planned analysis.Endologix CFO Departs, Announces Interim CEO Endologix, Inc. (NASDAQ: ELGX) said its CFO Vaseem Mahboob,will leave the company, effective July 1, to take over as CFO of a private global healthcare company.View more earnings on IBBThe company announced the appointment of Cindy Pinto, VP, Financial Planning & Analysis, as interim CFO in addition to her current responsibilities, and it also said it has initiated a search process for a permanent successor.Miragen Appoints Pharma Industry Veteran As COO Miragen Therapeutics Inc (NASDAQ: MGEN) announced the appointment of Lee Rauch as Chief Operating Officer, effective immediately. Rauch, who has over 25 years of experience in the biotech and pharma industries, will report to the CEO and will be responsible for overseeing business development, licensing, partnerships, investor relations, corporate communications, intellectual property, and new product planning, the company said.In pre-market trading, the stock was up 4.20% t $1.24.Akebia Names David Spellman as CFO Akebia Therapeutics Inc (NASDAQ: AKBA) said David Spellman is joining Akebia as its new SVP, Chief Financial Officer and Treasurer, effective June 29, replacing Jason Amello, who has been serving in the position since 2013.Dynavax Says Human Trial of COVID-19 Vaccine Using Its Adjuvant Initiated Dynavax Technologies Corporation (NASDAQ: DVAX) announced the first participants have been dosed in the Phase 1 clinical trial to evaluate Clover Biopharma's vaccine candidate to prevent COVID-19 that contains the Company's CpG 1018 adjuvant.In pre-market trading, Dynavax shares were rising 9.30% to $6.70.Earnings Urovant Sciences Ltd (NASDAQ: UROV) reported a net loss of $1.68 per share for its fiscal-year 2019 fourth quarter compared to a loss of 96 cents per share a year ago. This was wider than the consensus loss estimate of $1.24 per share.The stock was down 3.48% to $11.10 in pre-market trading.BioNano Genomics Inc's (NASDAQ: BNGO) first-quarter revenues fell from $1.8 million in 2019 to $1.1 million in 2020. The net loss widened from $7.8 million to $10.5 million.The stock was sliding 5.80% to 49 cents in pre-market trading.On The Radar PDUFA Dates Nabriva Therapeutics PLC - ADR (NASDAQ: NBRV) is knocking at the FDA altar for the second time for its investigational antibiotic contepo for treating complicated urinary tract infection. The company hinted at the decision being delayed due to the FDA requiring inspection of the facilities of third-party manufacturers in Europe.Evoke Pharma Inc (NASDAQ: EVOK) has a PDUFA date in the unfolding for its Gimoti to treat women with acute and recurrent diabetic gastroparesis.IPOs Repare Therapeutics Inc., a precision oncology company enabled by its proprietary synthetic lethality approach, priced its upsized initial public offering of 11 million shares of its common shares at $20 per share. Repare's common shares are expected to begin trading on the Nasdaq under the ticker symbol RPTX.Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, priced its IPO of 13.88 million shares at $20 per share. The shares are expected to begin trading on the Nasdaq under the ticker symbol FMTX.See more from Benzinga * The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions * The Daily Biotech Pulse: Patent Win For Amarin, FDA Nod For Novartis & Merck, Chembio's Coronavirus EUA Revoked * The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Benzinga

    P/E Ratio Insights for Alpine Immune Sciences

    In the current session, Alpine Immune Sciences Inc. (NASDAQ: ALPN) is trading at $9.87, after a 102.67% increase. Over the past month, the stock increased by 194.10%, and in the past year, by 123.24%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently higher from its 52 week high by 84.49%.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.Depending on the particular phase of a business cycle, some industries will perform better than others.Compared to the aggregate P/E ratio of the 4.13 in the Biotechnology industry, Alpine Immune Sciences Inc. has a lower P/E ratio of 0.0. Shareholders might be inclined to think that they might perform worse than its industry peers. It's also possible that the stock is undervalued.P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * A Look Into Spotify Technology's Price Over Earnings * Morning Market Stats in 5 Minutes * Benzinga's Top Upgrades, Downgrades For June 18, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Business Wire

    Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101

    Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101

  • Business Wire

    Alpine Immune Sciences Announces ALPN-202 Poster Presentation at AACR Virtual Annual Meeting II

    Alpine Immune Sciences Announces ALPN-202 Poster Presentation at AACR Virtual Annual Meeting II

  • Alpine Immune Sciences' Shares March Higher, Can It Continue?
    Zacks

    Alpine Immune Sciences' Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Alpine Immune Sciences.

  • Hedge Funds Never Been Less Bullish On Alpine Immune Sciences, Inc. (ALPN)
    Insider Monkey

    Hedge Funds Never Been Less Bullish On Alpine Immune Sciences, Inc. (ALPN)

    At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]

  • Business Wire

    Alpine Immune Sciences Provides Clinical Update of its Phase 1 Trial of ALPN-101 in Healthy Volunteers at the European League Against Rheumatism (EULAR) E-Congress 2020

    Alpine Immune Sciences Provides Clinical Update of its Phase 1 Trial of ALPN-101 in Healthy Volunteers at the European League Against Rheumatism

  • Business Wire

    Alpine Immune Sciences Presents Preclinical Data on Novel Dual BAFF/APRIL Inhibitory Domains for B cell Mediated Autoimmune Diseases at the European Congress of Rheumatology E-Congress 2020

    Alpine Immune Sciences Presents Preclinical Data on Novel Dual BAFF/APRIL Inhibitory Domains for B cell Mediated Autoimmune Diseases at the EULAR

  • Business Wire

    Alpine Immune Sciences Announces Poster Presentations at EULAR 2020

    Alpine Immune Sciences Announces Poster Presentations at EULAR 2020

  • Business Wire

    Alpine Immune Sciences to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference

    Alpine Immune Sciences to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference

  • Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported Earnings, And Analysts Cut Their Target Price
    Simply Wall St.

    Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported Earnings, And Analysts Cut Their Target Price

    Alpine Immune Sciences, Inc. (NASDAQ:ALPN) just released its quarterly report and things are looking bullish. Sales...

  • Business Wire

    Alpine Immune Sciences Reports First Quarter 2020 Financial Results and Provides Company Update

    Alpine Immune Sciences Reports First Quarter 2020 Financial Results and Provides Company Update

  • Business Wire

    Alpine Immune Sciences Presents Design of the ALPN-202 Phase 1 Study (NEON-1) at AACR Virtual Annual Meeting I

    Alpine Immune Sciences Presents Design of the ALPN-202 Phase 1 Study (NEON-1) at AACR Virtual Annual Meeting I

  • Business Wire

    Alpine Immune Sciences Announces Poster Presentation at AACR Virtual Annual Meeting I

    Alpine Immune Sciences Announces Poster Presentation at AACR Virtual Annual Meeting I

  • What You Must Know About Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Beta Value
    Simply Wall St.

    What You Must Know About Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Beta Value

    Anyone researching Alpine Immune Sciences, Inc. (NASDAQ:ALPN) might want to consider the historical volatility of the...

  • Business Wire

    Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

    Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2019.

  • ACCESSWIRE

    Alpine Immune Sciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 ...

  • Business Wire

    Alpine Immune Sciences’ ALPN-101 Receives FDA Orphan Drug Designations for the Prevention and Treatment of Acute Graft Versus Host Disease

    Alpine Immune Sciences, Inc. (NASDAQ:ALPN) , a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the United States Food and Drug Administration (FDA) has made two orphan drug designations for ALPN-101, Alpine’s first-in-class selective dual T cell costimulation inhibitor, for the prevention and for the treatment of acute GVHD.

  • Business Wire

    Alpine Immune Sciences Announces Cancellation of Presentation and Webcast at the Cowen 40th Annual Healthcare Conference

    Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced today the cancellation of the Company’s presentation and webcast at the Cowen 40th Annual Healthcare Conference scheduled for Tuesday, March 3, 2020 at 11:20 am. Eastern Time. The Company is taking precautionary measures in response to the evolving coronavirus (COVID-19) situation in the Seattle area.

  • Have Insiders Been Buying Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares This Year?
    Simply Wall St.

    Have Insiders Been Buying Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares This Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...